AI Engines For more Details: Perplexity Kagi Labs You
Heart Health: Safflower oil is rich in unsaturated fatty acids, particularly linoleic acid, which is an omega-6 fatty acid. Consuming safflower oil as part of a balanced diet may help improve cholesterol levels by increasing HDL (good) cholesterol and reducing LDL (bad) cholesterol. This can contribute to a reduced risk of heart disease and stroke.
Blood Sugar Control: Some studies suggest that safflower oil may have beneficial effects on blood sugar levels and insulin sensitivity, which could be beneficial for individuals with diabetes or those at risk of developing diabetes. However, more research is needed to confirm these effects.
Inflammation: Safflower oil contains compounds with anti-inflammatory properties, such as polyphenols and tocopherols. These compounds may help reduce inflammation in the body, which could be beneficial for individuals with inflammatory conditions such as arthritis, asthma, or inflammatory bowel disease (IBD).
Skin Health: Safflower oil is commonly used in skincare products due to its moisturizing and emollient properties. It may help improve skin hydration, reduce inflammation, and alleviate symptoms of conditions like eczema and psoriasis when applied topically.
Weight Management: Some research suggests that safflower oil supplementation may aid in weight loss or weight management by promoting fat loss and reducing abdominal adiposity. However, results from studies are mixed, and more research is needed to fully understand the role of safflower oil in weight management.
Liver Health: Preliminary studies suggest that safflower oil supplementation may have hepatoprotective effects, meaning it may help protect the liver from damage caused by toxins or disease. This could be beneficial for individuals with liver conditions such as fatty liver disease or hepatitis.
Menstrual Pain: Safflower seed extract has been traditionally used in Chinese medicine to alleviate menstrual pain and regulate menstrual cycles. Some research suggests that safflower extract may help reduce menstrual pain and improve symptoms of premenstrual syndrome (PMS), although more studies are needed to confirm these effects.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.2 | 0.2 | |
| ADHD | 0.7 | 0.5 | 0.4 |
| Allergic Rhinitis (Hay Fever) | 0.2 | 0.5 | -1.5 |
| Allergies | 0.3 | -0.3 | |
| Allergy to milk products | 0.2 | 0.5 | -1.5 |
| Alzheimer's disease | 2.2 | 2 | 0.1 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.7 | 0.3 | 4.67 |
| Ankylosing spondylitis | 1.2 | 0.7 | 0.71 |
| Anorexia Nervosa | 0.5 | 0.5 | |
| Antiphospholipid syndrome (APS) | 0.5 | -0.5 | |
| Asthma | 0.7 | 0.7 | 0 |
| Atherosclerosis | 0.2 | 0.5 | -1.5 |
| Atrial fibrillation | 0.5 | -0.5 | |
| Autism | 1.7 | 1.5 | 0.13 |
| Bipolar Disorder | 0.7 | 0.2 | 2.5 |
| Brain Trauma | 0.7 | -0.7 | |
| Breast Cancer | 0.5 | -0.5 | |
| Carcinoma | 0.5 | 0.2 | 1.5 |
| Celiac Disease | 1.2 | -1.2 | |
| Cerebral Palsy | 0.7 | 0.2 | 2.5 |
| Chronic Fatigue Syndrome | 0.2 | 0.7 | -2.5 |
| Chronic Kidney Disease | 0.2 | 0.5 | -1.5 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.8 | 0.8 | |
| Chronic Urticaria (Hives) | 0.3 | -0.3 | |
| Coagulation / Micro clot triggering bacteria | 0.2 | 0.2 | |
| Colorectal Cancer | 0.5 | 0.5 | |
| Constipation | 0.7 | -0.7 | |
| Coronary artery disease | 0.3 | 0.3 | |
| COVID-19 | 1 | 2 | -1 |
| Crohn's Disease | 1 | 1.5 | -0.5 |
| Depression | 2.2 | 1.3 | 0.69 |
| Eczema | 0.5 | 0.5 | |
| Endometriosis | 0.3 | 0.2 | 0.5 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 1.2 | 1.3 | -0.08 |
| Functional constipation / chronic idiopathic constipation | 0.7 | 1.2 | -0.71 |
| gallstone disease (gsd) | 0.2 | 0.2 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.2 | 0.2 | 0 |
| Glioblastoma | 0.5 | 0.2 | 1.5 |
| Gout | 0.5 | 0.5 | |
| Graves' disease | 0.7 | 0.5 | 0.4 |
| Halitosis | 0.5 | 0.5 | |
| Hashimoto's thyroiditis | 1 | 0.2 | 4 |
| Hemorrhoidal disease, Hemorrhoids, Piles | 0.5 | 0.5 | |
| Hidradenitis Suppurativa | 0.3 | 0.3 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.5 | -0.5 | |
| hypercholesterolemia (High Cholesterol) | 0.2 | 0.2 | 0 |
| hyperglycemia | 1.2 | -1.2 | |
| Hyperlipidemia (High Blood Fats) | 1 | 0.5 | 1 |
| hypertension (High Blood Pressure | 0.8 | 1.7 | -1.13 |
| Hypoxia | 1 | 0.2 | 4 |
| IgA nephropathy (IgAN) | 0.3 | -0.3 | |
| Inflammatory Bowel Disease | 0.3 | 0.7 | -1.33 |
| Insomnia | 0.5 | 0.2 | 1.5 |
| Intelligence | 1.2 | -1.2 | |
| Irritable Bowel Syndrome | 0.3 | 0.8 | -1.67 |
| Liver Cirrhosis | 1 | 1.2 | -0.2 |
| Long COVID | 3.2 | 2.5 | 0.28 |
| Lung Cancer | 0.2 | -0.2 | |
| Metabolic Syndrome | 2.5 | 3 | -0.2 |
| Mood Disorders | 4 | 1.8 | 1.22 |
| multiple chemical sensitivity [MCS] | 0.5 | 0.5 | |
| Multiple Sclerosis | 1.8 | 1 | 0.8 |
| Multiple system atrophy (MSA) | 0.7 | 0.7 | |
| Neuropathy (all types) | 0.5 | 0.5 | 0 |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.8 | 2 | -1.5 |
| Obesity | 1.2 | 1.5 | -0.25 |
| obsessive-compulsive disorder | 0.8 | -0.8 | |
| Osteoporosis | 0.5 | 0.7 | -0.4 |
| Parkinson's Disease | 2.2 | 0.8 | 1.75 |
| Polycystic ovary syndrome | 1.5 | 0.5 | 2 |
| Psoriasis | 0.8 | 1 | -0.25 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.8 | 1.7 | 0.06 |
| Schizophrenia | 2 | 0.7 | 1.86 |
| scoliosis | 0.2 | -0.2 | |
| Sjögren syndrome | 0.2 | 0.2 | 0 |
| Sleep Apnea | 0.5 | 0.5 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.2 | 0.2 | |
| Stress / posttraumatic stress disorder | 0.8 | 0.2 | 3 |
| Systemic Lupus Erythematosus | 1.2 | 0.8 | 0.5 |
| Tic Disorder | 0.2 | 0.7 | -2.5 |
| Tourette syndrome | 1 | 1 | |
| Type 1 Diabetes | 0.7 | 0.7 | 0 |
| Type 2 Diabetes | 2.3 | 1.5 | 0.53 |
| Ulcerative colitis | 0.5 | 2.3 | -3.6 |
| Unhealthy Ageing | 1.2 | -1.2 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.